Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy
- PMID: 28709702
- PMCID: PMC5698142
- DOI: 10.1016/j.ophtha.2017.05.038
Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy
Abstract
Purpose: To investigate the clinical and morphologic characteristics of serous retinal disturbances in patients taking mitogen-activated protein kinase kinase (MEK) inhibitors.
Participants: A total of 313 fluid foci in 50 eyes of 25 patients receiving MEK inhibitors for treatment of their metastatic cancer, who had evidence of serous retinal detachments confirmed by optical coherence tomography (OCT).
Design: Single-center, retrospective cohort study.
Methods: Clinical examination and OCT were used to evaluate MEK inhibitor-associated subretinal fluid. The morphology, distribution, and location of fluid foci were serially evaluated for each eye. Choroidal thickness was measured at each time point (baseline, fluid accumulation, and fluid resolution). Two independent observers performed all measurements. Statistical analysis was used to correlate interobserver findings and compare choroidal thickness and visual acuity at each time point.
Main outcome measures: Comparison of OCT characteristics of retinal abnormalities at baseline to fluid accumulation.
Results: The majority of patients had fluid foci that were bilateral (92%) and multifocal (77%) and at least 1 focus involving the fovea (83.3%). All fluid foci occurred between the interdigitation zone and an intact retinal pigment epithelium. The 313 fluid foci were classified into 4 morphologies, as follows: 231 (73.8%) dome, 36 (11.5%) caterpillar, 31 (9.9%) wavy, and 15 (4.8%) splitting. Best-corrected visual acuity at fluid resolution was not statistically different from baseline; and no eye lost more than 2 Snellen lines from baseline at the time of fluid accumulation. There was no statistical difference in the choroidal thickness between the different time points (baseline, fluid accumulation, and fluid resolution). A strong positive interobserver correlation was obtained for choroidal thickness measurements (r = 0.97, P < 0.0001) and grading of foci morphology (r = 0.97, P < 0.0001).
Conclusion: The subretinal fluid foci associated with MEK inhibitors have unique clinical and morphologic characteristics, which can be distinguished from the findings of central serous chorioretinopathy. In this series, MEK inhibitors did not cause irreversible loss of vision or serious eye damage.
Copyright © 2017 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Figures






Comment in
-
Re: Francis et al.: Clinical and morphologic characteristics of MEK inhibitor-associated retinopathy: differences from central serous chorioretinopathy (Ophthalmology. 2017;124:1788-1798).Ophthalmology. 2018 Apr;125(4):e30-e31. doi: 10.1016/j.ophtha.2017.11.001. Ophthalmology. 2018. PMID: 29566878 No abstract available.
-
Reply.Ophthalmology. 2018 Apr;125(4):e31. doi: 10.1016/j.ophtha.2017.11.002. Ophthalmology. 2018. PMID: 29566879 No abstract available.
References
-
- Turner MC, Rossfeld K, Salama AKS, et al. Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment? Expert Opin Pharmacother. 2017;18:487–495. - PubMed
-
- Dummer R, Schadendorf D, Ascierto PA, et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:435–445. - PubMed
-
- Liu CY, Francis JH, Brodie SE, et al. RETINAL TOXICITIES OF CANCER THERAPY DRUGS: Biologics, Small Molecule Inhibitors, and Chemotherapies. Retina (Philadelphia, Pa) 2014;34:1261–1280. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical